RECENT POSTS
FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our "Question of the Day" right now.
FULL SHOWSMissed an episode of Fast Money? Watch the lastest show here.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
Kris Jenner, M.D., lead portfolio manager for the T. Rowe Price Health Sciences Fund joins the panel for this conversation. Following is a summary of his main points.
Tell us about the drug.
AAB-001 is probably the most advanced product for Alzheimer’s, Jenner explains. And we’re going to get information over the next two months that will tell us about the probability of its success in Phase 3 trials.
The market is excited because there are approximately 7 million Alzheimer’s patients in the US and Western Europe. If only 1 million of those individuals get on this therapy at $10,000/ year that’s a 10 billion dollar drug!
Is it a cure?
It is not, replies Jenner. But it has the opportunity to really delay the very devastating effects. While not a cure, it could be a tremendous advance forward.
What are the odds it will make it to market?
I think the probabilities are good, replies Jenner, greater than 50/50. But we’re at a pivotal point so buyer beware. However, I think the upside here is unlike many other pharma opportunities.
Which comapny benefits most?
Elan [ELN
Loading...
()
] will have much higher reward but also higher risk, he says. With Wyeth [WYE
Loading...
()
] you would participate but not have the same upside. We have a larger position in Elan
On a related note, Myriad [MYGN
Loading...
()
] and Lilly [LLY
Loading...
()
] also have other Alzheimer’s drugs in the pipeline and could also be worth a look, adds Pete Najarian.
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to .
Trader disclosure: On Apr .7, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (YHOO), (MSFT); Pete Najarian Owns (AAPL), (NOK), (YHOO), (NVS), (XLF); Pete Najarian Owns (AA) Calls, (CHK) Calls, (MSFT) Calls, (BHI) Calls; Finerman Owns (GS); Finerman's Firm And Finerman Own (CROX); Finerman's Firm Owns (FLS), (MSFT), (YHOO); Finerman's Firm Is Short (IYR), (IJR), (MDY), (SPY), (IWM); T. Rowe Price Owns 1% Or More Of (MYGN): Guy Adami's Wife Works At Schering-Plough
Data is a real-time snapshot *Data is delayed at least 15 minutes